Piper Sandler Maintains Overweight on AnaptysBio, Lowers Price Target to $93

Benzinga Newsdesk www.benzinga.com Negative 73.6%

Neg 73.6% Neu 0% Pos 0%

Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $95 to $93.